Andrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, Miguel J Gil-Gil, Vinay K Puduvalli, Jeffrey J Raizer, Filip Y F De Vos, Patrick Y Wen, Nicholas A Butowski, Paul M J Clement, Morris D Groves, Cristóbal Belda-Iniesta, Pierre Giglio, Harris S Soifer, Steven Rowsey, Cindy Xu, Francesca Avogadri, Ge Wei, Susan Moran, Patrick Roth
PURPOSE: FGFR genomic alterations (amplification, mutations, and/or fusions) occur in ∼8% of gliomas, particularly FGFR1 and FGFR3. We conducted a multicenter open-label, single-arm, phase II study of a selective FGFR1-3 inhibitor, infigratinib (BGJ398), in patients with FGFR-altered recurrent gliomas. PATIENTS AND METHODS: Adults with recurrent/progressive gliomas harboring FGFR alterations received oral infigratinib 125 mg on days 1 to 21 of 28-day cycles. The primary endpoint was investigator-assessed 6-month progression-free survival (PFS) rate by Response Assessment in Neuro-Oncology criteria...
June 1, 2022: Clinical Cancer Research